EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The epidemiology and psychological comorbidity of disorders of gut–brain interaction in Australia: Results from the Rome Foundation Global Epidemiology Study

Simon R Knowles iD, Pragalathan Apputhurai iD, Olafur S Palsson iD, Shrikant Bangdiwala iD, Ami D Sperber iD, Antonina Mikocka-Walus iD

Neurogastroenterology & Motility · 2023

DOI: 10.1111/nmo.14594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurogastroenterology & Motility, 2023. Verfasst von Simon R Knowles und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Sciences, School of Health Sciences, Swinburne University of Technology, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Depression, Irritable Bowel Syndrome. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Allergan, Ironwood Pharmaceuticals, Incorporated, Shire.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Rome Foundation Global Epidemiology Study on the disorders of gut–brain interaction (DGBI) was used to assess the national prevalence of all 22 DGBI, the percentage of respondents meeting diagnostic criteria for at least one DGBI, and the rates of comorbid anxiety, depression, and somatization in Australia and 25 other countries.

Methods

The survey was conducted in Australia and 25 other countries through the Internet and included the Rome IV Diagnostic Questionnaire and an in‐depth supplemental questionnaire. Key Results Two thousand thirty‐six Australian adults completed the survey nationwide: mean age 47.34 ± 17.00 years, 50.15% males. Overall, 38.67% of Australians met criteria for at least one DGBI, with unspecified functional bowel disorder (8.01%) and then functional constipation (7.71%) being the most prevalent. For those Australians with at least one DGBI, rates of anxiety, depression, and somatization where high (26.58%, 28.96%, and 63.10%, respectively), with functional chest pain having the highest rates of anxiety (55.00%) and depression (57.50%), and irritable bowel syndrome (mixed) having the highest somatization rate (75.86%). The odds of having a DGBI increased with greater anxiety (OR: 1.09, CI 95%: 0.97, 1.23), depression (OR: 1.17, CI 95%: 1.04, 1.32), and somatization (OR: 1.17, CI 95%: 1.14, 1.20) symptom severity. Conclusions and Inferences The current study represents the most comprehensive epidemiological exploration of DGBI and mental health in Australia to date, including their prevalence and distributions across sex and age, associations between DGBI and anxiety, depression, and somatization. The findings warrants future comparisons between population characteristics and health care systems differences in order to reduce the burden of DGBI and mental illness worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepressionIrritable Bowel SyndromeAdultMaleHumansMiddle AgedFemaleRomeAustraliaComorbidityBrainSurveys and Questionnaires

Stichwörter der Autor:innen

AustraliaRome IV diagnostic criteriadisorders of gut-brain interactionepidemiologypsychological

Autor:innen und Institutionen

  • Department of Psychological Sciences, School of Health Sciences, Swinburne University of Technology, Melbourne, Victoria, Australia.
  • Department of Health Sciences and Biostatistics, School of Health Sciences, Swinburne University of Technology, Melbourne, Australia.
  • Center for Functional GI & Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

ORCID-Profile: Simon R Knowles, Pragalathan Apputhurai, Olafur S Palsson, Shrikant Bangdiwala, Ami D Sperber, Antonina Mikocka-Walus

Förderung

  • Allergan
  • Ironwood Pharmaceuticals, Incorporated
  • Shire
  • Takeda Pharmaceutical Company

Zitieren

APA

Knowles, S. R., Apputhurai, P., Palsson, O. S., Bangdiwala, S., Sperber, A. D., & Mikocka-Walus, A. (2023). The epidemiology and psychological comorbidity of disorders of gut–brain interaction in Australia: Results from the Rome Foundation Global Epidemiology Study. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14594

Vancouver

Knowles SR, Apputhurai P, Palsson OS, Bangdiwala S, Sperber AD, Mikocka-Walus A. The epidemiology and psychological comorbidity of disorders of gut–brain interaction in Australia: Results from the Rome Foundation Global Epidemiology Study. Neurogastroenterology & Motility. 2023. doi:10.1111/nmo.14594

BibTeX
@article{Knowles2023,
  author = {Knowles, Simon R and Apputhurai, Pragalathan and Palsson, Olafur S and Bangdiwala, Shrikant and Sperber, Ami D and Mikocka-Walus, Antonina},
  title = {The epidemiology and psychological comorbidity of disorders of gut–brain interaction in Australia: Results from the Rome Foundation Global Epidemiology Study},
  journal = {Neurogastroenterology & Motility},
  year = {2023},
  doi = {10.1111/nmo.14594}
}
Kostenlos starten →